Qurient Co., Ltd.

Amid continued weakness in general investor sentiment around initial public offerings (IPOs) and venture capital (VC) financings in the sector, South Korean biopharma companies increasingly opted for

A combination product containing Merck & Co., Inc. ’s Keytruda plus its investigational anti-TIGIT therapy, vibostolimab, has missed the mark in a Phase II lung cancer trial, adding to a spate of dis

The University of Texas MD Anderson Cancer Center and US/UK biotech Replay announced on 14 February that they are launching a new company, Syena, to advance research conducted at the cancer center o

While a series of South Korean companies are dropping out of the race to develop COVID-19 treatments and vaccines, others are managing to remain in the game, moving towards a goal of getting approvals